
Ten years ago, the zzso treating zzso zzso prostate cancer zzso had zzso options for treatment of symptomatic patients, such as the combination of zzso combined with zzso as well as isotope zzso In 2004, zzso chemotherapy regimens were shown to provide an overall survival benefit for patients with zzso Today, the prostate cancer zzso is in the enviable position of having six zzso Food and Drug zzso agents to choose zzso zzso zzso hormonal therapies zzso zzso zzso zzso and chemotherapy zzso zzso in addition to agents being administered in clinical zzso In general, the sequencing of these drugs is based upon the entry criteria from the phase III trials that led to their zzso zzso of treatment is based on symptoms, sites of disease zzso vs zzso and types of prior treatment zzso zzso zzso vs zzso zzso Unfortunately, there is a lack of useful zzso zzso in prostate cancer to help zzso select zzso This problem is best illustrated in the zzso zzso setting, for which there are indications to use all five other approved zzso In this review we will outline an approach to sequencing these new therapies, with particular attention paid to the biology of zzso 

